INTRODUCTION

Ischemia-reperfusion injury occurs when blood flow is disrupted and subsequently reintroduced. The rapid reintroduction of oxygen generates reactive oxygen species (ROS), leading to oxidative damage\(^1\). Oxidative damage is implicated in pathophysiological processes, including myocardial infarction and brain stroke\(^2\). To prevent oxidative damage to tissues, we must understand the molecular mechanisms underlying ROS generation and degradation during ischemia and reperfusion. ROS generation during ischemia and reperfusion results from a sequence of three steps. In the first step, ischemia occurs, which involves insufficient blood flow to provide adequate oxygenation, leading to tissues being exposed to hypoxia. Hypoxia induces and activates ROS generators, such as NADPH oxidases and xanthine oxidase. In the second step, the restoration of blood flow reintroduces oxygen into the affected area. In the third step, this re-oxygenation results in ROS generation as a natural byproduct of the normal metabolism of oxygen. Hypoxic ischemia causes the excessive generation of ROS\(^3\). In contrast, extra ROS accumulation is brought back to normal by the induction of antioxidant proteins. The levels of these proteins are increased by activation of their production at the transcriptional level in response to oxidative stress\(^4\). Antioxidant responsive elements AREs are cis-regulatory elements that are crucial for the expression of cytoprotective genes. Nrf2 is known to be a key transcriptional activator of AREs. Under normal conditions, Nrf2 is constantly degraded through the ubiquitin-proteasome pathway in a Keap1-mediated manner. Keap1 maintains steady-state levels of Nrf2 and blocks Nrf2-mediated transcription\(^5\). Moreover, under oxidative stress, oxidized substance
modify Keap1, leading to a conformational change in Keap1 and/or stress-mediated kinases modify Nrf2, leading to a conformational change in Nrf2. Either or both of these mechanisms allow the liberation of Nrf2 from Keap1, leading to the activation of AREs. In this manner, the regulation of Nrf2 under oxidative conditions is well characterized. However, despite the involvement of ROS during hypoxia in ischemia-reperfusion injury, the regulation of Nrf2 under hypoxic conditions has remained unclear. Hypoxia induces the phosphorylation of Nrf2; then Keap1-mediated degradation of Nrf2 is decreased compared with that under normoxia. In addition, hypoxia-induced Siah2 provides a dominating of Nrf2 degradation pathway stronger than over that by Keap1 under hypoxia. These phenomena suggest that Siah2 is involved in ROS metabolism. Therefore, in that case, Siah proteins would be attractive targets for effective therapy under particular conditions such as ischemia-reperfusion injury.

IDENTIFICATION OF SINA AND SIAH FAMILY

The seven in absentia (Sina) gene was originally identified in Drosophila. Murine and human homologs of the Sina gene have also been identified. In mice, Sina homologs (Siah) were isolated as three Siah proteins, Siah1a, Siah1b, and Siah2, which are encoded by different genes. In contrast, the human Siah proteins consist of two homologs, Siah1 and Siah2, which are encoded by the SIAH1 and SIAH2 genes, respectively, and apparently have distinct but overlapping functions.

FUNCTION OF SINA AND SIAH PROTEINS

The Sina protein is required for regulation of the R7 signaling pathway in photoreceptor cell development of Drosophila. The loss of functional Sina protein causes a deficiency of R7 precursor cells. Sina binds to the Sevenless pathway protein phyllopod (PHYL) and Ebi, and an ubiquitin ligase complex consisting of them target a transcriptional repressor, Tramtrack, for ubiquitin-dependent proteolysis, resulting in a cell-fate decision in the development of Drosophila eye.

In Xenopus, Siah2 is expressed maternally and is later restricted to the brain, spinal cord and developing and mature eyes. Siah2 overexpression during Xenopus development causes the small-eye phenotype.

On the other hand, in mammals, a similar ubiquitin ligase complex is formed and functions in ubiquitin-dependent proteolysis by the well-described anaphase-promoting complex (APC), Skp1/Cullin/F-box complex (SCF), and Siah/Ebi/Siah interacting protein (SIP) complex. Siah contains functional binding sites that recognize a peptide motif within many substrates and adaptors. Siah proteins bind to a highly conserved PxAxVxP motif in their substrates, and interact with numerous cellular proteins such as a transcriptional repressor, Tramtrack; peptide inhibitor, PHYL; the oncogenic protein, β-catenin; a nuclear receptor co-repressor, N-CoR; a motor protein Kid; and the tumor suppressor TGF-β induced early gene (TIEG). In some cases, such interaction requires an adaptor protein such as PHYL, and SIP to degrade Drosophila Tramtrack and mammalian β-catenin, respectively.

Siah proteins are potent RING finger E3 ubiquitin ligases that catalyze the ubiquitination of proteins, bind to E2 enzymes, and target their substrates for ubiquitin degradation. Siah2 is a RING finger type ubiquitin ligase with a catalytic RING domain on its N-terminus, followed by two zinc fingers and a C-terminal substrate binding domain (SBD). Siah2 limits its own availability through self-ubiquitination and is a known regulator of hypoxia-activated signaling pathways.

UPSTREAM SIGNALING PATHWAYS OF SIAH PROTEINS

Siah1 expression is enhanced by p53, which is activated by DNA damage. Expressed Siah1 is phosphorylated by ATM/ATR after DNA damage. The tumor suppressor HIPK2, which phosphorylates p53 at Ser 46, contributing to p53-mediated apoptosis induction, is a substrate of Siah proteins. The phosphorylation of Siah1 by ATM/ATR disrupts the interaction of HIPK2 and Siah1, thereby stabilizing HIPK2, resulting in the promotion of apoptosis induction.

Treatment with a chemical inhibitor against Phosphoinositide 3-kinase (PI3K) decreases Akt activity and the expression levels of hypoxia-induced Siah2 mRNA. The expression of Siah2 is induced when an active form of Akt is introduced into cells. Therefore, the Akt-dependent pathway may be one of the critical signaling pathways to induce Siah2, although the transcription factor that induces Siah2 mRNA is still unknown.

Siah2 is subjected to phosphorylation, which increases its activity under hypoxia. This phosphorylation of Siah2 is inhibited when cells are exposed to a chemical inhibitor against p38 mitogen-activated protein kinase (MAPK). Siah2 contains the SQ/TQ amino acid sequence motif, a conserved motif for p38 MAPK phosphorylation. S29 and T24 are major phosphorylation sites of Siah2. The phosphorylation of Siah2 by p38 MAPK results in stabilization and subsequent activation of the Siah2 protein in the cytoplasm.

In addition, the expression of Siah2 is up-regulated by estrogen in estrogen-receptor (ER)-positive breast cancer cells, in which Siah2 degrades the repressor of ER signaling, N-CoR, resulting in resistance to apoptosis induction and affecting mitochondrial function. Furthermore, ubiquitin specific peptidase 13 (USP13) reduces the substrate degradation activity of Siah2 protein with a concomitant inhibitory effect on activity of Siah2 under normoxia.

FUNCTION OF SIAH AS A TUMOR SUPPRESSOR PROTEIN AND ITS ROLE IN CANCER PROGRESSION

Increasing evidence indicates that Siah has an important role in tumor development and progression. Previous studies suggested the tumor suppressive role of Siah, particularly Siah1. The function of Siah in cancer progression was first investigated in pancreatic cancer. In human pancreatic cancer cells, overexpression of both mutated Siah1 and Siah2 was found to cause growth arrest. In addition, overexpression of Siah1 arrested the growth of hepatoma cells. Furthermore, the expression of Siah1 transplanted into U937 lymphoma cell suppressed the tumorigenesis of these cells when injected into nude mice. Finally, in other cancers, such as liver and gastric cancers, low levels of Siah1 expression promoted cancer progression.

A dominant negative Siah protein was also found to inhibit ERK signaling and cell proliferation, increase apoptosis induction, and reduce tumorigenesis of A549 human lung cancer cells, when injected into nude mice. In addition, inhibition of the expression of Siah had an anti-tumorigenic effect in mouse melanoma, SW1 cells,
and breast cancer cells\(^{37}\). Inhibition of the binding of Siah with the substrates through PHYL also reduced tumor growth, angiogenesis, and metastatic spread by the inactivated hypoxic response pathway\(^{38,39}\). Furthermore, in vivo, a chemical inhibitor of Siah2, menadione, abolished the growth of xenograft tumors in nude mice\(^{37}\). The genetic knockout of Siah proteins is valuable in establishing the significance of biochemical and cell biological studies. Finally, in both Siah1a and Siah2 null mice, tumor progression to an advanced stage was inhibited and metastasis was reduced\(^{41}\). These findings suggest that the inhibition of Siah expression is effective for attenuating tumor growth.

**FUNCTION OF SIAH IN HYPOXIC RESPONSE AND ITS ROLE IN MYOCARDIAL ISCHEMIA**

Hypoxia-inducible factor-1 (HIF-1) is a master transcriptional factor that plays a critical role in protecting cells against hypoxic stress within the range of physiological normoxia to mild hypoxia\(^{37}\). Under normal conditions, HIF-1 expression is regulated by the hydroxylation of its proline residues\(^{38,39}\). Siah2 protein targets prolyl hydroxylases (PHD) 3 and 1 that are responsible for this function for degradation, concomitantly facilitating HIF-1 stabilization under an oxygen concentration of 2%-5%\(^{39}\). The loss of Siah2 attenuates HIF-1 protein expression levels, leading to decreased proliferation, and increased apoptosis induction in cancer cells. In Siah2 knockout mice, tumor onset was found to be delayed; in addition, the mice exhibited an abrogated response to hypoxic conditions. At cellular and tissue levels, the expression of Siah2 mutants under hypoxic conditions led to significantly lower protein levels of HIF-1, resulting in reduced hypoxia-induced gene expression\(^{38,39}\).

Recent studies have also suggested that NF-E2-related factor (Nrf2), which plays an important role in ROS metabolism, is negatively regulated by Siah2 under stressful conditions\(^{37-40}\). Under basal conditions, Nrf2 is phosphorylated by protein kinase C (PKC), which triggers the release from Keap1. Knockdown of Siah2 rescues hypoxia-induced reduction of both Nrf2 mutants mimicking phosphorylation at Ser40 and lacking this phosphorylation site, suggesting that Siah2 contributes to the degradation of Nrf2 irrespective of its phosphorylation status\(^{37}\) (Figure 1). In addition, the knockdown of Siah2, but not Keap1, was shown to significantly attenuate the hypoglycemia-mediated reduction of Nrf2 expression\(^{41}\).

Mitochondria are critical for cell survival, and their morphology is associated with susceptibility to cell death signals\(^{41}\). In ischemia-induced cardiomyocyte cell death, Siah2 regulates the availability of the mitochondrial scaffolding protein AKAP121 and subsequent mitochondrial dynamics. Reduced availability of AKAP121 due to Siah2 relieves Drp1 inhibition by PKA and increases its interaction with Fis1, resulting in mitochondrial fission. In cells lacking Siah2, the level of this fission is decreased and ischemia-induced apoptosis of cardiomyocytes is reduced.

RNAi inhibition of both Siah1 and Siah2 reduces infarct size while improving cardiac function after ischemia-reperfusion injury of hearts. Moreover, in vivo RNAi inhibition of both Siah1 and Siah2 was found to augment the cardioprotective function of netrin-1\(^{42}\).

**FUNCTION OF SIAH IN ROS METABOLISM**

The major sources of ROS, including mitochondria, NADPH oxidases, xanthine oxidase, and Ca\(^{2+}\) flux, are activated...
during ischemic hypoxia, representing important cytotoxic mechanisms\(^5\). ROS causes lipid peroxidation as well as protein and DNA oxidation, and it also stimulates ischemic cells to secrete inflammatory cytokines and chemokines that induce cell damage. Cellular oxidative stress defense systems are tightly regulated through the synthesis and degradation of many transcriptional factors such as Nrf2\(^5\). Ischemia reperfusion generates ROS and leads to cellular damage and oxidative stress in hypoxia and subsequent reoxygenation.

The role of Siah1/2 in ROS production and degradation remains unclear; however, some studies have suggested that inhibition of the expression and function of Siah might be an attractive approach to impair ROS metabolism. Interfering with Nrf2 down-regulation through Siah inhibition is effective to induce the expression of cytoprotective genes\(^7\), as it may have an impact on the cellular adaptive responses to oxidative stress more broadly than the inhibition of Keap1 alone.

**CONCLUSION**

Siah2 protein is a regulator of several signaling pathways such as ER, HIF-1\(α\), and Ras. Recent work has demonstrated that Siah2 protein is a promising therapeutic target in pathological conditions accompanied by a low level of Nrf2 expression\(^8\)\(^9\). The inhibition of Siah2 expression restores the decreased expression of Nrf2-inducible genes and subsequently improves symptoms. Past data focuses on the Siah2 protein expression in vivo models. Furthermore, the incidence of Nrf2 and Siah2 interaction genes and subsequently improves symptoms. Past data focuses on the Siah2 expression restores the decreased expression of Nrf2-inducible protein is a promising therapeutic target in pathological conditions.

**REFERENCES**

1. Raedschelders K, Ansley DM, Chen DD. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. *Pharmacol Ther* 2012; 133: 230-255.
2. Nour M, Scalzo F, Liebeskind D. Ischemia-reperfusion injury in stroke. *Interv Neurul* 2013; 1: 185-199.
3. Clanton TL. Hypoxia-induced reactive oxygen species formation in skeletal muscle. *J Appl Physiol* 2007; 102: 237923-237988.
4. Lee JM, Johnson JA. An important role of Nrf2-ARE pathway in the cellular defense mechanism. *J Biochem Mol Biol* 2004; 37: 139-143.
5. Itoh K, Wakabayashi N, Kato Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev* 1999; 13: 76-86.
6. Zhang DD, Hannik M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. *Mol Cell Biol* 2003; 23: 8137-8151.
7. Baba K, Morimoto H, Imaoka S, Imaoka S. Seven in absentia homolog 2 (Siah2) protein is a regulator of NF-E2-related factor 2 (Nrf2). *J Biol Chem* 2013; 288: 18393-18405.
8. Carthew RW, Rubin GM. Seven in absentia, a gene required for specification of R7 cell fate in the Drosophila eye. *Cell* 1990; 63: 561-757.
9. Della NG, Senior PV, Bowtell DL. Isolation and characterization of murine homologues of the Drosophila seven in absentia gene (sina). *Development* 1993; 117: 1333-43.
10. Holloway AJ, Della NG, Fletcher CF, Largespada DA, Copeland NG, Jenkins NA, Bowtell DD. Isolation and characterization of murine homologues of the Drosophila seven in absentia gene (sina). *Genomics* 1997; 41: 160-168.
11. Carthew RW, Neufeld TP, Rubin GM. Identification of genes that interact with the sina gene in Drosophila eye development. *Proc Natl Acad Sci U S A* 1994; 91: 11689-11693.
12. Tang AH, Neufeld TP, Kwan E, Rubin GM. PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-development mechanism. *Cell* 1997; 90: 459-67.
13. Bogdan S, Senkel S, Esser F, Ryffel GU, Pogge E, Strandmann V. Strandmann v. Misexpression of Xsiah-2 induces a small eye phenotype in Xenopus. *Mech. Dev* 2001; 103: 61-69.
14. Conaway RC, Brover CS, Conaway JW. Emerging roles of ubiquitin in transcription regulation. *Science* 2002; 296: 1254-1258.
15. Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi co;aborate in a novel pathway for beta-catenin degradation linked to p53 responses. *Mol Cell* 2001; 7: 915-926.
16. House CM, Hancock NC, Moller A, Cromer BA, FEodorov V, Bowtell DL, Parker MW. Elucidation of the substrate binding site of Siah ubiquitin ligase. *Structure* 2006; 14, 695-701.
17. House CM, Frew JI, Huang HL, Wiche G, Traffante N, Nice E, Catimel B, Bowtell DL. A binding motif for Siah ubiquitin ligase. *Proc Natl Acad Sci U S A* 2003; 100: 3101-3106.
18. Frasor J, Danes JM, Funk CC, Katzenellenbogen BS. Estrogen down-regulation of the coressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes. *Proc Natl Acad Sci U S A* 2005; 102: 13153-13157.
19. Germani A, Buxtoni-Giovannielli H, Fellous A, Gisselbrecht S, Varin-Binck N, Calvo F. SIAH-1 interacts with alpha-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis. *Oncogene* 2000; 19: 5997-6006.
20. Johnsen SA, Subramaniam M, Monroe DG, Janknecht R, Spelsberg TC. Modulation of transforming growth factor beta (TGF-beta)/Smad transcriptional responses through targeted degradation of TGFbeta-inducible early gene-1 by human seven in absentia homologue. *J Biol Chem* 2002; 277: 30754-30759.
21. Hu G, Fearon ER. Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins. *Mol Cell Biol* 1999; 19: 13724-13732.
22. Nakayama K, Qi J, Ronai Z. The ubiquitin ligase Siah2 and the hypoxia response. *Mol Cancer Res* 2009; 7: 443-451.
23. Matsuzawa S, Takayama S, Froesch BA, Zapata JM, Reed JC. p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. *EMBO J* 1998; 17: 2736-2747.
24. D’Orazi G, Cecchinelli B, Bruno T, Manni I, Ghiashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanucidii M, Appella E, Solda S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. *Nat Cell Biol* 2002; 4: 11-19.
25. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. *Genes Dev* 2000; 14: 391-396.
26. Khurana A, Nakayama K, Williams S, Davis R, Mustelin T, Ronai Z. Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. *J Biol Chem* 2006; 281: 35316-35326.
27. Scortegagna M, Subtil T, Qi J, Kim H, Zhao W, Gu W, Kluger H, Ronai Z. USP13 enzyme regulates Siah2 ligase stability and activity via a noncatalytic ubiquitin-binding domains. *J Biol Chem* 2011; 286: 27333-27341.
28. Schmidt RL, Park CH, Ahmed AU, Gundelaeh JH, Reed NR, Cheng S, Knudsen BE, Tang AH. Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. *Cancer Res* 2007; 67: 11798-11810.

29. Yoshibayashi H, Okabe H, Satoh S, Hida K, Kawashima K, Hamasu S, Nomura A, Hasegawa S, Ikai I, Sakai Y. SIAH1 causes growth arrest and apoptosis in hepatoma cells through beta-catenin degradation-dependent and –independent mechanisms. *Oncol Rep* 2007; 17: 549-556.

30. Roperch J, Lethrone F, Prieur S, Piouffre L, Israeli D, Tuynder M, Nemani M, Pasturaud P, Gendron M, Dausset J, Oren M, Anson RB, Telerman A. SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1). *Proc Natl Acad U S A* 1999; 96: 8070-8073.

31. Kim CJ, Cho YG, Park CH, Jeong SW, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY, Park WS. Inactivating mutations of the Siah-1 gene in gastric cancer. *Oncogene* 2004; 23: 8591-8596.

32. Ahmed AU, Schmidt RL, Park CH, Reed NR, Hesse SE, Thomas CF, Molina JR, Deschamps C, Yang P, Aubry MC, Tang AH. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. *J Natl Cancer Inst* 2008; 100: 1606-1629.

33. Wong CS, Sceneay J, House CM, Halse HM, Liu MC, George J, Hunnam TC, Parker BS, Haviv I, Ronai Z, Cullinane C, Bowtell DD, Moller A. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy. *Cancer Res* 2012; 72: 1694-1704.

34. Qi J, Nakayama K, Gaitonde S, Goydos JS, Krajewski S, Eroshkin A, Bar-Sagi D, Bowtell D, Ronai Z. The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and –independent pathways. *Proc Natl Acad Sci U S A* 2008; 105: 16713-16718.

35. Shah M, Stebbins JL, Dewing A, Qi J, Pellecchia M, Ronai Z. Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. *Pigment Cell Melanoma Res* 2009; 22: 799-808.

36. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai Z. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. *Cancer Cell* 2010; 18: 23-38.

37. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci U S A* 1993; 90: 4304-4308.

38. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. *Sem Cell Dev Biol.* 2002; 13: 29-37.

39. McNeill LA, Hewitson KS, Gleadle JM. The use of dioxygen by HIF prolyl hydroxylase (PHD1). *Bioorg Med Chem Lett* 2002; 12: 1547-1550.

40. Sajja RK, Green KN, Cucullo L. Altered Nrf2 signaling mediates hypoglycemia-induced blood-brain barrier endothelial dysfunction in vitro. *PLos One* 2015; 10: e0122358.

41. Kim H, Scimia MC, Wilkinson D, Trelles RD, Wood MR, Bowtell D, Dillin A, Mercola M, Ronai ZA. Fine-tuning of Drp1/Fis1 availability by AKAP121/Siah2 regulates mitochondrial adaptation to hypoxia. *Mot Cell* 2011; 44: 532-544.

42. Li Q, Wang P, Ye K, Cai H. Central role of SIAH inhibition in DCC-dependent cardioprotection provoked by netrin-1/NO. *Proc Natl Acad Sci U S A* 2015; 112: 899-904.

**Peer reviewer:** Zufeng Ding, PhD, Department of Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.